BIOLOGIC RESPONSE-MODIFYING AGENTS - WHAT IS AN APPROPRIATE PHASE-I-II STRATEGY

被引：0
|
作者：
CARTER, SK
机构：
[1] STANFORD UNIV,STANFORD,CA 94305
[2] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143
来源：
CANCER IMMUNOLOGY IMMUNOTHERAPY | 1980年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：207 / 210
页数：4
相关论文
共 50 条
  • [1] Implications of Rheumatic Disease and Biological Response-Modifying Agents in Plastic Surgery
    Oranges, Carlo M.
    Schaefer, Dirk J.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2016, 138 (01) : 158E - 158E
  • [2] Implications of Rheumatic Disease and Biological Response-Modifying Agents in Plastic Surgery
    Tsai, David M.
    Borah, Gregory L.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2015, 136 (06) : 1327 - 1336
  • [3] INTRACAVITARY PHASE-I-II METHOTREXATE
    CONROY, T
    WEBER, B
    GUILLEMIN, F
    KRAKOWSKI, I
    LUPORSI, E
    METZ, R
    BULLETIN DU CANCER, 1986, 73 (04) : 430 - 430
  • [4] Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes
    O'Doherty, Catherine
    Villoslada, Pablo
    Vandenbroeck, Koen
    CYTOKINE & GROWTH FACTOR REVIEWS, 2007, 18 (3-4) : 211 - 222
  • [5] MAYTANSINE (M), A PHASE-I-II STUDY
    BLUM, RH
    WITTENBERG, BK
    CANELLOS, GP
    MAYER, RJ
    SKARIN, AT
    LOKICH, JJ
    HENDERSON, IC
    PARKER, LM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 399 - 399
  • [6] ISOTOPIC IMMUNOGLOBULIN THERAPY - PHASE-I-II TRIAL
    ORDER, SE
    KLEIN, JL
    SGAGIAS, M
    ETTINGER, D
    TRUMP, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 366 - 366
  • [7] ORAL CYTEMBENA ABSORPTION AND PHASE-I-II STUDIES
    NEIDHART, JA
    STAUBUS, AE
    YOUNG, D
    BALCERZAK, SP
    MALSPEIS, L
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 401 - 404
  • [8] PHASE-I-II TRIAL OF MITOXANTRONE IN ACUTE-LEUKEMIA
    ARLIN, ZA
    SILVER, R
    CASSILETH, P
    ARMENTROUT, S
    GAMS, R
    DAGHESTANI, A
    COLEMAN, M
    SCHOCH, I
    DUKART, G
    CANCER TREATMENT REPORTS, 1985, 69 (01): : 61 - 64
  • [9] A PHASE-I-II STUDY OF MAYTANSINE UTILIZING A WEEKLY SCHEDULE
    FRANKLIN, R
    SAMSON, MK
    FRAILE, RJ
    ABUZAHRA, H
    OBRYAN, R
    BAKER, LH
    CANCER, 1980, 46 (05) : 1104 - 1108
  • [10] The ethics of phase I trials of biologic agents
    Hanauer, Stephen B.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2008, 5 (10): : 533 - 533
12345